Vaccine Research

ProMetic expands DNA purification collaboration

Published in Gene Therapy Weekly, May 29th, 2003

ProMetic BioSciences, the Canadian wholly owned subsidiary of ProMetic Life Sciences, Inc., (PLI), and Aldevron, LLC, announced the expansion of their successful collaboration to develop and market a new technology for the purification of gene therapy and DNA vaccine products.

The agreement leverages ProMetic's strengths in designing purification resins with Aldevron's expertise in the field of plasmid DNA manufacturing.

Aldevron is currently using ProMetic's Perflurosorb S as part of a process to manufacture a West Nile Virus (WNV) DNA vaccine for the Center for Disease Control (CDC). Perflurosorb S is normally used to remove impurities (such as...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-05-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry